HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Clinical trial NCT03387553 · COMPLETED

Trial details

NCT number: NCT03387553
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Status: COMPLETED
Phase: Early Phase 1
Study type: INTERVENTIONAL

Breast Cancer Breast Cancer Female Breast Cancer, Male Invasive Breast Cancer HER2-positive Breast Cancer HER2 Positive Breast Carcinoma Stage II Breast Cancer Stage III Breast Cancer

Start date: 2018-06-06
Primary completion: 2023-08-29
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.